Fadi Haddad/X
Sep 8, 2024, 07:17
Fadi Haddad: Very encouraging results with ‘dose-dense’ miniHCV + InO + Blina in Relapsed or Refractory ALL
Fadi Haddad shared on X:
“Very encouraging results with ‘dose-dense’ miniHCV + InO + Blina in Relapsed or Refractory ALL
22 patients
Treatment schema detailed below
High rates of MRD negativity by flow (95%) and NGS (94%)
Transplant in 4 patients
2-year OS = 79%”
Source: Fadi Haddad/X
More Posts featuring Fadi Haddad on oncodaily.com
Fadi Haddad is an Assistant Professor in the Department of Leukemia, Division of Cancer Medicine, at the The University of Texas MD Anderson Cancer Center. He earned his MD from Saint Joseph University, Beirut. He completed his residencyin Hematology/Oncology, from Hotel Dieu de France Hospital.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 04:33
Feb 22, 2025, 04:29
Feb 22, 2025, 04:19
Feb 22, 2025, 03:56
Feb 22, 2025, 03:52